Actions of Syros Pharma (NASDAQ:SYRS) rose 2.2% in pre-market trading after the company released its fourth quarter results.
Earnings per share declined 34.78% over the past year to ($ 0.62), which missed the estimate of ($ 0.50).
Revenue of $ 5,698,000 up 1021.65% year over year, exceeding estimate of $ 2,700,000.
Profit forecasts have not been released by the company at this time.
Syros Pharmaceuticals has not released a revenue forecast at this time.
How to listen to the conference call
Date: 04 March 2021
Time: 8:30 a.m.
Webcast URL AND: https://edge.media-server.com/mmc/p/u2m2ncg6
The 52-week company high was $ 15.65
The company’s 52-week low was at $ 4.26
Price action in the last quarter: Up 0.71%
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. She is primarily involved in the segments of the pharmaceutical, biotechnology and other related markets that deal with gene control and cancer. The Company operates only in the United States.
See more Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.